Clinical Pharmacology and Therapeutics 1995: Vol 58 Index

15 Pages·1995·3.7 MB·English

Index to volume 58
Author index
A Braun RE (see Margarone et al). 1995;58:453-8
Abernethy DR, Laurie N, Andrawis NS. Local angiotensin-con- Brown A (see Welch et al). 1995;58:132-42
verting enzyme inhibition blunts endothelin-1—induced increase Brown JS, Bienz-Tadmor B, Lasagna L. Availability of anticancer
in forearm vascular resistance. 1995;58:328-34 drugs in the United States, Europe, and Japan from 1960 through
1991. 1995;58:243-56 (Commentary)
Acott PD (see McLellan et al). 1995;58:322-7
Affrime MB (see Brannan et al). 1995;58:269-78 Brown M( see Stein et al). 1995;58:425-33
— (see Hulsman et al). 1995;58:383-9 Brunelle RL (see Howey et al). 1995;58:459-69
— (see Reidenberg et al). 1995;58:279-87 Bushell E (see Bedarida et al). 1995;58:73-80
— (see Saano et al). 1995;58:523-31
Agrawal S (see Zhang et al). 1995;58:44-53 Cc
Albrecht R (see Hughes et al). 1995;58:434-43
Caraco Y, Tateishi T, Wood AJJ. Interethnic difference in omepra-
Amin G (see Zhang et al). 1995;58:44-53
zole’s inhibition of diazepam metabolism. 1995;58:62-72
Andrawis NS (see Abernethy et al). 1995;58:328-34
— (see Zylber-Katz et al). 1995;58:198-209
Antal EJ (see Hughes et al). 1995;58:434-43
Carbonin P (see Pahor et al). 1995;58:470-81
Antoni G (see Hartvig et al). 1995;58:165-73
Carleborg L (see Spigset et al). 1995;58:399-403
Anttila M (see Huupponen et al). 1995;58:506-11
Carosella L (see Pahor et al). 1995;58:470-81
Asthana S, Greig NH, Hegedus L, Holloway HH, Raffaele KC,
Cayen MN (see Brannan et al). 1995;58:269-78
Schapiro MB, Soncrant TT. Clinical pharmacokinetics of
Cecchi E (see Pahor et al). 1995;58:470-81
physostigmine in patients with Alzheimer’s disease. 1995;58:299-
309 Chandrasekar PH (see Ducharme et al). 1995;58:617-24
Chiang ST (see van Griensven et al). 1995;58:631-40
Chiba K (see Ishizaki et al). 1995;58:155-64
B — (see Yasuda et al). 1995;58:143-54
Bagatin J (see Rumboldt et al). 1995;58:237-8 (Letter) Choma N (see Mould et al). 1995;58:35-43
Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug Cipollone F, Ganci A, Panara MR, Greco A, Cuccurullo F, Patrono
safety discontinuations in the United Kingdom, the United States, C, Patrignani P. Effects of nabumetone on prostanoid biosynthe-
and Spain from 1974 through 1993: a regulatory perspective. sis in humans. 1995;58:335-41
1995;58:108-17 Clipp EC, Moore MJ. Caregiver time use: an outcome measure in
Banfield CR (see Hulsman et al). 1995;58:383-9 clinical trial research on Alzheimer’s disease. 1995;58:228-36
— (see Reidenberg et al). 1995;58:279-87 Cocchi A (see Pahor et al). 1995;58:470-81
— (see Saano et al). 1995;58:523-31 Cohen AF (see van Griensven et al). 1995;58:631-40
Barbey JT (see Yasuda et al). 1995;58:210-20 Colangelo PM (see Harris et al). 1995;58:310-5
Barbhaiya RH, Shukla UA, Natarajan CS, Behr DA, Greene DS, Colucci RD (see Hulsman et al). 1995;58:383-9
Sainati SM. Single- and multiple-dose pharmacokinetics of nefa- — (see Reidenberg et al). 1995;58:279-87
zodone in patients with hepatic cirrhosis. 1995;58:390-8 — (see Saano et al). 1995;58:523-31
Barchowsky A (see Cutler et al). 1995;58:54-61 Conrad KA. Clinical pharmacology and drug safety: lessons from
Barre J (see Plaud et al). 1995;58:185-91 hirudin. 1995;58:123-6 (Commentary)
Bedarida G, Bushell E, Blaschke TF, Hoffman BB. H,- and H,-his- Crews T (see Mould et al). 1995;58:35-43
tamine receptor—mediated vasodilation varies with aging in Crocker JFS (see McLellan et al). 1995;58:322-7
humans. 1995;58:73-80 Cuccurullo F (see Cipollone et al). 1995;58:335-41
Behr DA (see Barbhaiya et al). 1995;58:390-8 Cutler NR, Seifert RD, Schleman MM, Sramek JJ, Szylleyko OJ,
Benet LZ (see Gomez et al). 1995;58:15-9 Howard DR, Barchowsky A, Wardle TS, Brass_ EP.
— (see Wu et al). 1995;58:492-7 Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics
Benowitz NL, Jacob P III, Mayan H, Denaro C. Sympathomimetic and pharmacodynamics. 1995;58:54-61
effects of paraxanthine and caffeine in humans. 1995;58:684-91
Berlin I. Buspirone miosis. 1995;58:600-1 (Letter)
D
—, Said S, Spreux-Varoquaux O, Launay JM, Olivares R, Millet V,
Lecrubier Y, Puech AJ. A reversible monoamine oxidase A D’ Agostino RB, Weintraub M. Meta-analysis: a method for synthe-
inhibitor (moclobemide) facilitates smoking cessation and absti- sizing research. 1995;58:605-16 (Commentary)
nence in heavy, dependent smokers. 1995;58:444-52 Dahl R (see Welch et al). 1995;58:132-42
Bernabei R (see Pahor et al). 1995;58:470-81 Dahlqvist R (see Spigset et al). 1995;58:399-403
Bienz-Tadmor B (see Brown et al). 1995;58:243-56 (Commentary) Dannenberg AJ (see Kashfi et al). 1995;58:625-30
Bjornsson TD (see Lo et al). 1995;58:641-9 Dayer P (see Transon et al). 1995;58:412-7
Blaschke TF (see Bedarida et al). 1995;58:73-80 de Abajo F (see Bakke et al). 1995;58:108-17
Bléchl-Daum B, Pehamberger H, Kurz C, Kyrle PA, Wagner O, Debaene B (see Plaud et al). 1995;58:185-91
Miiller M, Monitzer B, Eichler HG. Effects of cisplatin on urinary DeFeo TM (see Mould et al). 1995;58:35-43
thromboxane B, excretion. 1995;58:418-24 de Groot R (see van den Anker et al). 1995;58:650-9
Bowsher RR (see Howey et al). 1995;58:459-69 Delaney C (see Kostis et al). 1995;58:660-5
Brannan MD, Reidenberg P, Radwanski E, Shneyer L, Lin CC, de Morais SMF, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H,
Cayen MN, Affrime MB. Loratadine administered concomitantly Xiao ZS, Ile N, Zhou HH. Genetic analysis of the S-mephenytoin
with erythromycin: pharmacokinetic and electrocardiographic polymorphism in a Chinese population. 1995;58:404-11
evaluations. 1995;58:269-78 Denaro C (see Benowitz et al). 1995;58:684-91
Brass EP (see Cutler et al). 1995;58:54-61 Desai N (see Oo et al). 1995;58:548-55
CLINICAL PHARMACOLOGY & THERAPEUTICS DECEMBER 1995 705
CLINICAL PHARMACOLOGY & THERAPEUTICS
706 Author index DECEMBER 1995
Diasio RB (see Lu et al). 1995;58:512-22 — (see Reidenberg et al). 1995;58:279-87
— (see Zhang et al). 1995;58:44-53 — (see Saano et al). 1995;58:523-31
DiMasi JA. Success rates for new drugs entering clinical testing in Golczynska A, Lenders JWM, Goldstein DS. Glucocorticoid-
the United States. 1995;58:1-14 (Commentary) induced sympathoinhibition in humans. 1995;58:90-8
Doenicke A, Moss J, Lorenz W, Hoernecke R. Intravenous mor- Goldberg MR (see Lo et al). 1995;58:641-9
phine and nalbuphine increase histamine and catechola- Goldstein DS (see Golczynska et al). 1995;58:90-8
mine release without accompanying hemodynamic changes. Goldstein JA (see de Morais et al). 1995;58:404-11
1995;58:81-9 Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ.
Dohi Y (see Sato et al). 1995;58:583-7 The effects of ketoconazole on the intestinal metabolism and
Domino EF (see Kishimoto et al). 1995;58:666-74 bioavailability of cyclosporine. 1995;58:15-9
Downing-Shelton J (see Howey et al). 1995;58:459-69 — (see Wu et al). 1995;58:492-7
Dreisbach AW, Ferencz N, Hopkins NE, Fuentes MG, Rege AB, Gordin A (see Illi et al). 1995;58:221-7
George WJ, Lertora JJL. Urinary excretion of 6-hydroxychlor- Granit L (see Zylber-Katz et al). 1995;58:198-209
zoxazone as an index of CYP2E1 activity. 1995;58:498-505 Greco A (see Cipollone et al). 1995;58:335-41
Drobitch RK (see McLellan et al). 1995;58:322-7 Greene DS (see Barbhaiya et al). 1995;58:390-8
Ducharme MP, Slaughter RL, Warbasse LH, Chandrasekar PH, Van Greig NH (see Asthana et al). 1995;58:299-309
de Velde V, Mannens G, Edwards DJ. Itraconazole and hydroxy- Griese EU (see Fromm et al). 1995;58:374-82
itraconazole serum concentrations are reduced more than tenfold Gruppo Italiano di Farmacovigilanza nell’ Anziano (see Pahor et
by phenytoin. 1995;58:617-24 al). 1995;58:470-81
Guillaume M (see Reidenberg et al). 1995;58:279-87
Gupta SK (see Wu et al). 1995;58:492-7
E
Gustafsson LL (see Hartvig et al). 1995;58:165-73
Edwards DJ (see Ducharme et al). 1995;58:617-24
Egan TE (see Fiset et al). 1995;58:567-82
H
Eichler HG (see Bléchl-Daum et al). 1995;58:418-24
Elkins L (see Stoltz et al). 1995;58:342-53 Ha HR (see Kupferschmidt et al). 1995;58:20-8
Eller M (see Harris et al). 1995;58:310-5 Hadidi HF, Irshaid YM, Woosley RL, Idle JR, Flockhart DA. S-
Mephenytoin hydroxylation phenotypes in a Jordanian popula-
tion. 1995;58:542-7
F
Haefeli WE (see Peduzzi et al). 1995;58:675-83
Fanciullacci M, Geppetti P. Buspirone miosis. 1995;58:601 (Letter Hall RE (see Margarone et al). 1995;58:453-8
reply) Hansen SR (see Straka et al). 1995;58:29-34
Fattinger KE, Verotta D. Estimating bioavailability when clearance Haring P (see Saano et al). 1995;58:523-31
changes in time: the effect of model misspecification. Harris S, Hilligoss DM, Colangelo PM, Eller M, Okerholm R.
1995;58:595-9 (Letter) Azithromycin and terfenadine: lack of drug_ interaction.
Ferencz N (see Dreisbach et al). 1995;58:498-505 1995;58:310-5
Fiset P, Lemmens HLM, Egan TE, Shafer SL, Stanski DR. Hartvig P, Valtysson J, Lindner KJ, Kristensen J, Karlsten R,
Pharmacodynamic modeling of the electroencephalographic Gustafsson LL, Persson J, Svensson JO, @ye I, Antoni G,
effects of flumazenil in healthy volunteers sedated with midazo- Westerberg G, Langstrém B. Central nervous system effects of
lam. 1995;58:567-82 subdissociative doses of (S)-ketamine are related to plasma and
Flockhart DA (see Hadidi et al). 1995;58:542-7 brain concentrations measured with positron emission tomogra-
Fong J, Johnston S, Valentino T, Notterman D. Length/serum crea- phy in healthy volunteers. 1995;58: 165-73
tinine ratio does not predict measured creatinine clearance in crit- Hayashi M (see Ishizaki et al). 1995;58:155-64
ically ill children. 1995;58:192-7 He H (see Stein et al). 1995;58:425-33
Francom SF (sez Hughes et al). 1995;58:434-43 Hebert MF (see Gomez et al). 1995;58:15-9
Freeman A (see Gertz et al). 1995;58:288-98 — (see Wu et al). 1995;58:492-7
Fromm MF, Hofmann U, Griese EU, Mikus G. Dihydrocodeine: a Hedenmalm K( see Spigset et al). 1995;58:399-403
new opioid substrate for the polymorphic CYP2D6 in humans. Hegedus L (see Asthana et al). 1995;58:299-309
1995;58:374-82 Hilligoss DM (see Harris et al). 1995;58:310-5
Fuentes MG (see Dreisbach et al). 1995;58:498-505 Hoernecke R (see Doenicke et al). 1995;58:81-9
Fuhr U, Kummert AL. The fate of naringin in humans: A key to Hoffman BB (see Bedarida et al). 1995;58:73-80
grapefruit juice—drug interactions? 1995;58:365-73 Hofmann U (see Fromm et al). 1995;58:374-82
Fumagalli S (see Pahor et al). 1995;58:470-81 Holland SD (see Gertz et al). 1995;58:288-98
Funck-Brentano C (see Partovian et al). 1995;58:257-63 Holloway HH (see Asthana et al). 1995;58:299-309
Furtek CI (see Lo et al). 1995;58:641-9 Hop WCJ (see van den Anker et al). 1995;58:650-9
Hopkins NE (see Dreisbach et al). 1995;58:498-505
Horai Y (see Ishizaki et al). 1995;58:155-64
G
— (see Yasuda et al). 1995;58:143-54
Gambassi G (see Pahor et al). 1995;58:470-81 Howard DR (see Cutler et al). 1995;58:54-61
Ganci A (see Cipollone et al). 1995;58:335-41 Howey DC, Bowsher RR, Brunelle RL, Rowe HM, Santa
Garbutt-Sculli L (see Jamieson et al). 1995;58:594 PF, Downing-Shelton J, Woodworth JR. [Lys(B28), Pro(B29)]—
Garland WT (see Kostis et al). 1995;58:660-5 human insulin: effect of injection time on postprandial glycemia.
George WJ (see Dreisbach et al). 1995;58:498-505 1995;58:459-69
Geppetti P (see Fanciullacci and Geppetti). 1995;58:601 (Letter Huang Jd (see Lai et al). 1995;58:264-8
reply) Huang SL (see de Morais et al). 1995;58:404-11
Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Hughes GS Jr, Yancey EP, Albrecht R, Locker PK, Francom SF,
Quan H, Lasseter KC, Mucklow JC, Porras AG. Studies of the Orringer EP, Antal EJ, Jacobs EE Jr. Hemoglobin-based oxygen
oral bioavailability of alendronate. 1995;58:288-98 carrier preserves submaximal exercise capacity in humans.
Glue P (see Hulsman et al). 1995;58:383-9 1995;58:434-43
CLINICAL PHARMACOLOGY & THERAPEUTICS
VOLUME 58, NUMBER 6 Author index 707
Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. Plasma con- Kostis JB, Garland WT, Delaney C, Norton J, Liao We. Fosinopril:
centrations of triazolam are increased by concomitant ingestion of pharmacokinetics and pharmacodynamics in congestive heart
grapefruit juice. 1995;58:127-31 failure. 1995;58:660-5
Hulsman JARJ, Rentmeester TW, Banfield CR, Reidenberg P, Koyama E (see Ishizaki et al). 1995;58:155-64
Colucci RD, Meehan JW, Radwanski E, Mojaverian P, Lin CC, Krahenbiihl S (see Kupferschmidt et al). 1995;58:20-8
Nezamis J, Affrime MB, Glue P. Effects of felbamate on the phar- Kristensen J (see Hartvig et al). 1995;58:165-73
macokinetics of the monohydroxy and dihydroxy metabolites of Kroon R (see van Griensven et al). 1995;58:631-40
oxcarbazepine. 1995;58:383-9 Kuhn RJ (see Oo et al). 1995;58:548-55
Huupponen R, Karhuvaara S, Anttila M, Vuorilehto L, Scheinin H. Kummert AL (see Fuhr and Kummert). 1995;58:365-73
Buccal delivery of an 0,-adrenergic receptor antagonist, atipame- Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbiihl S.
zole, in humans. 1995;58:506-11 Interaction between grapefruit juice and midazolam in humans.
1995;58:20-8
I Kurz C (see Bléchl-Daum et al). 1995;58:418-24
Kyrle PA (see Bléchl-Daum et al). 1995;58:418-24
Idle JR (see Hadidi et al). 1995;58:542-7
Ile N (see de Morais et al). 1995;58:404-11
L
Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M,
Gordin A. The effect of entacapone on the disposition and hemo- Lai MD (see Lai et al). 1995;58:264-8
dynamic effects of intravenous isoproterenol and epinephrine. Lai ML, Wang SL, Lai MD, Lin ET, Tse M, Huang Jd. Propranolol
1995;58:221-7 disposition in Chinese subjects of different CYP2D6 genotypes.
Irshaid YM (see Hadidi et al). 1995;58:542-7 1995;58:264-8
Ishizaki T, Chiba K, Manabe K, Koyama E, Hayashi M, Yasuda S, Lanct6ét KL, Naranjo CA. Comparison of the Bayesian approach
Horai Y, Tomono Y, Yamato C, Toyoki T. Comparison of the inter- and a simple algorithm for assessment of adverse drug events.
action potential of a new proton pump inhibitor, E3810, versus 1995;58:692-8
omeprazole with diazepam in extensive and poor metabolizers of Langstrém B (see Hartvig et al). 1995;58:165-73
S-mephenytoin 4’-hydroxylation. 1995;58:155-64 Lasagna L (see Bakke et al). 1995;58:108-17
— (see Yasuda et al). 1995;58:143-54 — (see Brown et al). 1995;58:243-56 (Commentary)
Lasseter KC (see Gertz et al). 1995;58:288-98
J Launay JM (see Berlin et al). 1995;58:444-52
Laurie N (see Abernethy et al). 1995;58:328-34
Jacob P III (see Benowitz et al). 1995;58:684-91 Lecrubier Y (see Berlin et al). 1995;58:444-52
Jacobs EE Jr (see Hughes et al). 1995;58:434-43 Leemann T (see Transon et al). 1995;58:412-7
Jacqz-Aigrain E (see Partovian et al). 1995;58:257-63 Lemkes HHPJ (see van Griensven et al). 1995;58:631-40
Jaehde U, Sérgel F, Reiter A, Sig] G, Naber KG, Schunack W. Lemmens HLM (see Fiset et al). 1995;58:567-82
Effect of probenecid on the distribution and elimination of Lenders JWM (see Golczynska et al). 1995;58:90-8
ciprofloxacin in humans. 1995;58:532-41 Lerman J (see Spahr-Schopfer et al). 1995;58:316-21
Jaillon P (see Partovian et al). 1995;58:257-63 Lertora JJL (see Dreisbach et al). 1995;58:498-505
Jamieson MJ, Garbutt-Sculli L, Shepherd AMM. Miscompliance Levy M (see Zylber-Katz et al). 1995;58:198-209
by proxy. 1995;58:594 Liao We (see Kostis et al). 1995;58:660-5
Jensen PK (see Saano et al). 1995;58:523-31 Liebow C (see Margarone et al). 1995;58:453-8
Jiang Z (see Zhang et al). 1995;58:44-53 Likhari P (see Yasuda et al). 1995;58:210-20
Johnston S (see Fong et al). 1995;58:192-7 Limjuco R (see Mould et al). 1995;58:35-43
Jorch U (see Spahr-Schopfer et al). 1995;58:316-21 Lin CC (see Brannan et al). 1995;58:269-78
Jusko WJ (see van Griensven et al). 1995;58:631-40 — (see Hulsman et al). 1995;58:383-9
— (see Reidenberg et al). 1995;58:279-87
K — (see Saano et al). 1995;58:523-31
Lin ET (see Lai et al). 1995;58:264-8
Kadoya C (see Kishimoto et al). 1995;58:666-74 Linder L (see Peduzzi et al). 1995;58:675-83
Kaitin KI (see Bakke et al). 1995;58:108-17 Lindner KJ (see Hartvig et al). 1995;58:165-73
Kalhorn TF (see Mitra et al). 1995;58:556-66 Liu T (see Zhang et al). 1995;58:44-53
Karhuvaara S (see Huupponen et al). 1995;58:506-11 Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson
Karim A, Piergies A. Verapamil stereoisomerism: enantiomeric TD. Pharmacokinetics of losartan, an angiotensin II receptor
ratios in plasma dependent on peak concentrations, oral input rate, antagonist and its active metabolite EXP3174 in humans.
or both. 1995;58:174-84 1995;58:641-9
Karlsson M (see Sheiner and Karlsson). 1995;58:599-600 (Letter Locker PK (see Hughes et al). 1995;58:434-43
reply) Lorenz W (see Doenicke et al). 1995;58:81-9
Karlsten R (see Hartvig et al). 1995;58:165-73 Lu H (see Lo et al). 1995;58:641-9
Kashfi K, McDougall CJ, Dannenberg AJ. Comparative effects of Lu YQ (see de Morais et al). 1995;58:404-11
omeprazole on xenobiotic metabolizing enzymes in the rat and Lu Z, Zhang R, Diasio RB. Population characteristics of hepatic
human. 1995;58:625-30 dihydropyrimidine dehydrogenase activity, a key metabolic
Keundjian A (see Partovian et al). 1995;58:257-63 enzyme in 5-fluorouracil chemotherapy. 1995;58:5 12-22
Kharasch ED (see Mitra et al). 1995;58:556-66 — (see Zhang et al). 1995;58:44-53
Kishimoto T, Kadoya C, Sneyd R, Samra SK, Domino EF. Luo X (see Sonnichsen et al). 1995;58:99-107
Topographic electroencephalogram of propofol-induced con-
scious sedation. 1995;58:666-74
M
Kline WF (see Gertz et al). 1995;58:288-98
Kobayashi K (see Yasuda et al). 1995;58:143-54 Manabe K (see Ishizaki et al). 1995;58: 155-64
Kojima M (see Sato et al). 1995;58:583-7 — (see Yasuda et al). 1995;58:143-54
Korhonen P (see Illi et al). 1995:58:221-7 Mannens G (see Ducharme et al). 1995;58:617-24
CLINICAL PHARMACOLOGY & THERAPEUTICS
708 Author index DECEMBER 1995
Manocchia M (see Bakke et al). 1995;58:108-17 P
Manto A (see Pahor et al). 1995;58:470-81 Pahor M, Cecchi E, Fumagalli S, Manto A, Pedone C, Carosella L,
Marchionni N (see Pahor et al). 1995;58:470-81 Cocchi A, Bernabei R, Gambassi G, Marchionni N, Mugelli A,
Margarone JE, Liebow C, Hall RE, Braun RE, Weiner M. A com- Carbonin P, Gruppo Italiano di Farmacovigilanza nell’ Anziano.
parison of crossover versus parallel-group design in the evalua- Association of serum creatinine and age with headache caused by
tion of analgesic efficacy after molar extraction. 1995;58:453-8
nitrates. 1995;58:470-81
Martin RR (see Zhang et al). 1995;58:44-53 PalmerJ (see Spahr-Schopfer et al). 1995;58:316-21
Mathew P (see Sonnichsen et al). 1995;58:99-107 Panara MR (see Cipollone et al). 1995;58:335-41
Matuszewski BK (see Gertz et al). 1995;58:288-98 Partovian C, Jacqz-Aigrain E, Keundjian A, Jaillon P, Funck-
Mayan H (see Benowitz et al). 1995;58:684-91 Brentano C. Comparison of chloroguanide and mephenytoin for
McCrea JB (see Lo et al). 1995;58:641-9 the in vivo assessment of genetically determined CYP2C19 activ-
McDougall CJ (see Kashfi et al). 1995;58:625-30 ity in humans. 1995;58:257-63
McLellan DH (see McLellan et al). 1995;58:322-7 Patel IH (see Mould et al). 1995;58:35-43
McLellan RA, Drobitch RK, McLellan DH, Acott PD, Crocker JFS, — (see Zhi et al). 1995;58:487-91 (Commentary)
Renton KW. Norfloxacin interferes with cyclosporine disposition Patrignani P (see Cipollone et al). 1995;58:335-41
in pediatric patients undergoing renal transplantation. 1995; Patrono C (see Cipollone et al). 1995;58:335-41
58:322-7 Pedone C (see Pahor et al). 1995;58:470-81
McNamara PJ (see Oo et al). 1995;58:548-55 Peduzzi P, Simper D, Linder L, Strobel WM, Haefeli WE.
Meehan JW (see Hulsman et al). 1995;58:383-9 Neuropeptide Y in human hand veins: pharmacologic charac-
— (see Reidenberg et al). 1995;58:279-87 terization and interaction with cyclic guanosine monophos-
— (see Saano et al). 1995;58:523-31 phate—dependent venodilators in vivo. 1995;58:675-83
Meier PJ (see Kupferschmidt et al). 1995;58:20-8 Pehamberger H (see Bléchl-Daum et al). 1995;58:418-24
Meistelman C (see Plaud et al). 1995;58:185-91 Persson J (see Hartvig et al). 1995;58:165-73
Mikus G (see Fromm et al). 1995;58:374-82 Piergies A (see Karim and Piergies). 1995;58:174-84
Milla G (see Mould et al). 1995;58:35-43 Plaud B, Proost JH, Wierda MKH, Barre J, Debaene B, Meistelman
Millet V (see Berlin et al). 1995;58:444-52 C. Pharmacokinetics and pharmacodynamics of rocuronium at the
Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD, vocal cords and the adductor pollicis in humans. 1995;58:185-91
Slattery JT. Metabolism of dapsone to its hydroxylamine by Porras AG (see Gertz et al). 1995;58:288-98
CYP2E1 in vitro and in vivo. 1995;58:556-66 Proost JH (see Plaud et al). 1995;58:185-91
Mojaverian P (see Hulsman et al). 1995;58:383-9 Puech AJ (see Berlin et al). 1995;58:444-52
— (see Reidenberg et al). 1995;58:279-87
Monitzer B (see Bléchl-Daum et al). 1995;58:418-24
Moore MJ (see Clipp and Moore). 1995;58:228-36 Q
Moss J (see Doenicke et al). 1995;58:81-9 Quan H (see Gertz et al). 1995;58:288-98
Mould DR, DeFeo TM, Reele S, Milla G, Limjuco R, Crews T,
Choma N, Patel IH. Simultaneous modeling of the pharmacoki-
R
netics and pharmacodynamics of midazolam and diazepam.
1995;58:35-43 Radwanski E (see Brannan et al). 1995;58:269-78
Mucklow JC (see Gertz et al). 1995;58:288-98 — (see Hulsman et al). 1995;58:383-9
Mugelli A (see Pahor et al). 1995;58:470-81 — (see Reidenberg et al). 1995;58:279-87
Miiller M (see Blochl-Daum et al). 1995;58:418-24 — (see Saano et al). 1995;58:523-31
Mungall D (see White et al). 1995;58:588-93 Raffaele KC (see Asthana et al). 1995;58:299-309
Rakhit A (see Zhi et al). 1995;58:487-91 (Commentary)
Ravitch J (see Welch et al). 1995;58:132-42
N
Reele S (see Mould et al). 1995;58:35-43
Naber KG (see Jaehde et al). 1995;58:532-41 Rege AB (see Dreisbach et al). 1995;58:498-505
Nakai H (see Yasuda et al). 1995;58:143-54 Reidenberg P, Glue P, Banfield CR, Colucci RD, Meehan JW,
Naranjo CA (see Lanctét and Naranjo). 1995;58:692-8 Radwanski E, Mojaverian P, Lin CC, Nezamis J, Guillaume M,
Natarajan CS (see Barbhaiya et al). 1995;58:390-8 Affrime MB. Effects of felbamate on the pharmacokinetics of
Neijens HJ (see van den Anker et al). 1995;58:650-9 phenobarbital. 1995;58:279-87
Nelson R (see Stein et al). 1995;58:425-33 — (see Brannan et al). 1995;58:269-78
Neuvonen PJ (see Hukkinen et al). 1995;58:127-31 — (see Hulsman et al). 1995;58:383-9
Nezamis J (see Hulsman et al). 1995;58:383-9 — (see Saano et al). 1995;58:523-31
— (see Reidenberg et al). 1995;58:279-87 Reiter A (see Jaehde et al). 1995;58:532-41
Nomeir A (see Saano et al). 1995;58:523-31 Relling MV (see Sonnichsen et al). 1995;58:99-107
Norton J (see Kostis et al). 1995;58:660-5 Rentmeester TW (see Hulsman et al). 1995;58:383-9
Notterman D (see Fong et al). 1995;58:192-7 Renton KW (see McLellan et al). 1995;58:322-7
Reynolds D (see Stoltz et al). 1995;58:342-53
O Ribeiro RC (see Sonnichsen et al). 1995;58:99-107
Romano P (see White et al). 1995;58:588-93
Ojala-Karlsson P (see Illi et al). 1995;58:221-7 Rowe HM (see Howey et al). 1995;58:459-69
Okerholm R (see Harris et al). 1995;58:310-5 Rowland M (see Wu et al). 1995;58:492-7
Olivares R (see Berlin et al). 1995;58:444-52 Rumboldt Z, Bagatin J, Sardeli¢ S. The role of oral dihydroergota-
Olkkola KT (see Hukkinen et al). 1995;58:127-31 mine in the management of vascular disorders. 1995;58:237-8
Oo CY, Kuhn RJ, Desai N, McNamara PJ. Active transport of cime- (Letter)
tidine into human milk. 1995;58:548-55
Orisakwe OE (see Ufearo and Orisakwe). 1995;58:354-9
S
Orringer EP (see Hughes et al). 1995;58:434-43
Oye I (see Hartvig et al). 1995;58:165-73 Saag MS (see Zhang et al). 1995;58:44-53
CLINICAL PHARMACOLOGY & THERAPEUTICS
VOLUME 58, NUMBER 6 Author index 709
Saano V, Glue P, Banfield C, Reidenberg P, Colucci RD, Meehan J, Svensson JO (see Hartvig et al). 1995;58:165-73
Haring P, Radwanski E, Nomeir A, Lin CC, Jensen PK, Affrime Szylleyko OJ (see Cutler et al). 1995;58:54-61
MB. Effects of felbamate on the pharmacokinetics of a low-dose
combination oral contraceptive. 1995;58:523-31 T
Said S (see Berlin et al). 1995;58:444-52
Sainati SM (see Barbhaiya et al). 1995;58:390-8 Tateishi T (see Caraco et al). 1995;58:62-72
Salazar D (see Stoltz et al). 1995;58:342-53 Temsamani J (see Zhang et al). 1995;58:44-53
Samra SK (see Kishimoto et al). 1995;58:666-74 Thummel KE (see Mitra et al). 1995;58:556-66
Santa PF (see Howey et al). 1995;58:459-69 Tomlanovich SJ (see Gomez et al). 1995;58:15-9
Sardeli¢ S (see Rumboldt et al). 1995;58:237-8 (Letter) Tomono Y (see Ishizaki et al). 1995;58:155-64
Sato K, Sawada M, Kojima M, Dohi Y. Biphasic pressor responses — (see Yasuda et al). 1995;58:143-54
to norepinephrine in humans. 1995;58:583-7 Toyoki T (see Ishizaki et al). 1995;58:155-64
Sauer PJJ (see van den Anker et al). 1995;58:650-9 Transon C, Leemann T, Vogt N, Dayer P. In vivo inhibition pro-
Sawada M (see Sato et al). 1995;58:583-7 file of cytochrome P450TB (CYP2C9) by (+)-fluvastatin.
Schapiro MB (see Asthana et al). 1995;58:299-309 1995;58:412-7
Schechter PJ (see Zhang et al). 1995;58:44-53 Tse M (see Lai et al). 1995;58:264-8
Scheinin H (see Huupponen et al). 1995;58:506-11
Scheinin M (see Illi et al). 1995;58:221-7 U
Schleman MM (see Cutler et al). 1995;58:54-61
Ufearo CS, Orisakwe OE. Restoration of normal sperm character-
Schoemaker RC (see van den Anker et al). 1995;58:650-9
istics in hypoprolactinemic infertile men treated with metoclo-
Schunack W (see Jaehde et al). 1995;58:532-41
pramide and exogenous human prolactin. 1995;58:354-9
Seay RE, Brundage RC, Jensen PD, Schilling CG, Edgren BE.
Unadkat JD (see Mitra et al). 1995;58:556-66
Population pharmacokinetics of vancomycin in neonates
(1994;56:169-75). 1995;58:142 (Correction)
V
Seifert RD (see Cutler et al). 1995;58:54-61
Shafer SL (see Fiset et al). 1995;58:567-82 Valentino T (see Fong et al). 1995;58:192-7
Shahinian H (see Zhang et al). 1995;58:44-53 Valtysson J (see Hartvig et al). 1995;58:165-73
Sheiner LB, Karlsson M. Estimating bioavailability when clearance van den Anker JN, Schoemaker RC, Hop WCJ, van der Heijden BJ,
changes in time: the effect of model misspecification. Weber A, Sauer PJJ, Neijens HJ, de Groot R. Ceftazidime phar-
1995;58:599-600 (Letter reply) macokinetics in preterm infants: effects of renal function and ges-
—, Verotta D. Further notes on physiologic indirect response mod- tational age. 1995;58:650-9
els. 1995;58:238-40 (Letter) van der Heijden BJ (see van den Anker et al). 1995;58:650-9
Shepherd AMM (see Jamieson et al). 1995;58:594 Van de Velde V (see Ducharme et al). 1995;58:617-24
Shneyer L (see Brannan et al). 1995;58:269-78 van Griensven JMT, Jusko WJ, Lemkes HHPJ, Kroon R, Verhorst
Shukla UA (see Barbhaiya et al). 1995;58:390-8 CJ, Chiang ST, Cohen AF. Tolrestat pharmacokinetic and phar-
Sig] G (see Jaehde et al). 1995;58:532-41 macodynamic effects on red blood cell sorbitol levels in normal
Sikich N (see Spahr-Schopfer et al). 1995;58:316-21 volunteers and in patients with insulin-dependent diabetes.
Simper D (see Peduzzi et al). 1995;58:675-83 1995;58:63 1-40
Slattery JT (see Mitra et al). 1995;58:556-66 Varhe A (see Hukkinen et al). 1995;58:127-31
Slaughter RL (see Ducharme et al). 1995;58:617-24 Verhorst CJ (see van Griensven et al). 1995;58:63 1-40
Sneyd R (see Kishimoto et al). 1995;58:666-74 Verotta D (see Fattinger and Verotta). 1995;58:595-9 (Letter)
Soncrant TT (see Asthana et al). 1995;58:299-309 — (see Sheiner and Verotta). 1995;58:238-40 (Letter)
Sonnichsen DS, Ribeiro RC, Luo X, Mathew P, Relling MV. Vogt N (see Transon et al). 1995;58:412-7
Pharmacokinetics and pharmacodynamics of 21-day continuous Vuorilehto L (see Huupponen et al). 1995;58:506-11
oral etoposide in pediatric patients with solid tumors. 1995;58:99-
107
Ww
Sérgel F (see Jaehde et al}. 1995;58:532-41
Spahr-Schopfer IA, Lerman J, Sikich N, Palmer J, Jorch U. Wacher VJ (see Gomez et al). 1995;58:15-9
Pharmacokinetics of intravenous ondansetron in healthy children — (see Wu et al). 1995;58:492-7
undergoing ear, nose, and throat surgery. 1995;58:316-21 Wagner O (see Bléchl-Daum et al). 1995;58:418-24
Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R. Effect of cig- Walker PF (see Straka et al). 1995;58:29-34
arette smoking on fluvoxamine pharmacokinetics in humans. Wang SL (see Lai et al). 1995;58:264-8
1995;58:399-403 Warbasse LH (see Ducharme et al). 1995;58:617-24
Spreux-Varoquaux O (see Berlin et al). 1995;58:444-52 Wardle TS (see Cutler et al). 1995;58:54-61
Sramek JJ (see Cutler et al). 1995;58:54-61 Weber A (see van den Anker et al). 1995;58:650-9
Stanski DR (see Fiset et al). 1995;58:567-82 Weiner M (see Margarone et al). 1995;58:453-8
Stein CM, Nelson R, Brown M, He H, Wood M, Wood AJJ. Dietary Weintraub M (see D’Agostino and Weintraub). 1995;58:605-16
sodium intake modulates systemic but not forearm norepineph- (Commentary)
rine release. 1995;58:425-33 Weir S (see Stoltz et al). 1995;58:342-53
Stoltz M, Reynolds D, Elkins L, Salazar D, Weir S. Welch RM, Brown A, Ravitch J, Dahl R. The in vitro degradation
Pharmacokinetics and pharmacodynamics of the monoamine oxi- of cisatracurium, the R, cis-R’-isomer of atracurium, in human
dase B inhibitor mofegiline assessed during a phase I dose toler- and rat plasma. 1995;58:132-42
ance trial. 1995;58:342-53 Wellstein A (see Yasuda et al). 1995;58:210-20
Straka RJ, Hansen SR, Walker PF. Comparison of the prevalence of Westerberg G (see Hartvig et al). 1995;58:165-73
the poor metabolizer phenotype for CYP2D6 between 203 White RH, Zhou H, Romano P, Mungall D. Changes in plasma war-
Hmong subjects and 280 white subjects residing in Minnesota. farin levels and variations in steady-state prothrombin times.
1995;58:29-34 1995;58:588-93
Strobel WM (see Peduzzi et al). 1995;58:675-83 Wierda MKH (see Plaud et al). 1995;58:185-91
Sundberg S (see Illi et al). 1995;58:221-7 Wood AJJ (see Caraco et al). 1995;58:62-72
CLINICAL PHARMACOLOGY & THERAPEUTICS
710 Author index
DECEMBER 1995
— (see Stein et al). 1995;58:425-33 — (see Ishizaki et al). 1995;58:155-64
Wood M (see Stein et al). 1995;58:425-33 Yasuda SU, Wellstein A, Likhari P, Barbey JT, Woosley RL.
Woodworth JR (see Howey et al). 1995;58:459-69 Chlorpheniramine plasma concentration and histamine H,-recep-
Woosley RL (see Hadidi et al). 1995;58:542-7 tor occupancy. 1995;58:210-20
— (see Yasuda et al). 1995;58:210-20
Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY,
Z
Wacher VJ. Differentiation of absorption and first-pass gut and
hepatic metabolism in humans: studies with cyclosporine. Zhang R, Yan J, Shahinian H, Amin G, Lu Z, Liu T, Saag MS, Jiang
1995;58:492-7 Z, Temsamani J, Martin RR, Schechter PJ, Agrawal S, Diasio RB.
Pharmacokinetics of an anti-human immunodeficiency virus
X antisense oligodeoxynucleotide phosphorothioate (GEM 91) in
HIV-infected subjects. 1995;58:44-53
Xia H (see de Morais et al). 1995;58:404-11 — (see Lu et al). 1995;58:512-22
Xiao ZS (see de Morais et al). 1995;58:404-11 Zhi J, Rakhit A, Patel TH. Effects of dietary fat on drug absorption.
Xie HG (see de Morais et al). 1995;58:404-11 1995;58:487-91 (Commentary)
Zhou HH (see de Morais et al). 1995;58:404-11
Y Zhou H (see White et al). 1995;58:588-93
Ziegler WH (see Kupferschmidt et al). 1995;58:20-8
Yamato C (see Ishizaki et al). 1995;58:155-64
Zylber-Katz E, Caraco Y, Granit L, Levy M. Dipyrone metabolism
— (see Yasuda et al). 1995;58:143-54
in liver disease. 1995;58:198-209
Yan J (see Zhang et al). 1995;58:44-53
Yancey EP (see Hughes et al). 1995;58:434-43
Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K,
Kobayashi K, Chiba K, Ishizaki T. Comparison of the kinetic dis-
position and metabolism of E3810, a new proton pump inhibitor,
and omeprazole in relation to S-mephenytoin 4’-hydroxylation
status. 1995;58:143-54
Subject index
Angiotensin-converting enzyme inhibitors
Local angiotensin-converting enzyme inhibition blunts endothelin-
Acetylcholinesterases
l—-induced increase in forearm vascular resistance (Abernethy et al).
Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics and 1995;58:328-34
pharmacodynamics (Cutler et al). 1995;58:54-61
Angiotensin II
Adductor pollicis muscle
Pharmacokinetics of losartan, an angiotensin II receptor antagonist and
Pharmacokinetics and pharmacodynamics of rocuronium at the vocal its active metabolite EXP3174 in humans (Lo et al). 1995;58:641-9
cords and the adductor pollicis in humans (Plaud et al). 1995;58:185-
91 Antiemetics
Pharmacokinetics of intravenous ondansetron in healthy children
Adefovir
undergoing ear, nose, and throat surgery (Spahr-Schopfer et al).
Adefovir (USAN List No. 373). 1995;58:122 1995;58:316-21
Administration, buccal Antineoplastics
Buccal delivery of an ,-adrenergic receptor antagonist, atipamezole, in Availability of anticancer drugs in the United States, Europe, and
humans (Huupponen et al). 1995;58:506-11 Japan from 1960 through 1991 (Brown et al). 1995;58:243-56
Adverse drug reactions (Commentary)
Comparison of the Bayesian approach and a simple algorithm for Antisense oligodeoxynucleotides; see Oligonucleotides, antisense
assessment of adverse drug events (Lanct6ét and Naranjo).
1995;58:692-8 Arteflene
Arteflene (USAN List No. 376). 1995;58:484
Age factors
Atipamezole
Association of serum creatinine and age with headache caused by
Buccal delivery of an o,-adrenergic receptor antagonist, atipamezole, in
nitrates (Pahor et al). 1995;58:470-81
humans (Huupponen et al). 1995;58:506-11
H,- and H,-histamine receptor—mediated vasodilation varies with aging
in humans (Bedarida et al). 1995;58:73-80 Atracurium
The in vitro degradation of cisatracurium, the R, cis-R’-isomer of
Alendronate
atracurium, in human and rat plasma (Welch et al). 1995;58:132-42
Studies of the oral bioavailability of alendronate (Gertz et al).
1995;58:288-98 Azithromycin
Azithromycin and terfenadine: lack of drug interaction (Harris et al).
Algorithms
Comparison of the Bayesian approach and a simple algorithm for 1995;58:310-5
assessment of adverse drug events (Lanct6ét and Naranjo).
1995;58:692-8
Alpha adrenergic receptors; see Receptors, adrenergic, alpha Balafilcon A
Alzheimer’s disease Balafilcon A (USAN List No. 377). 1995;58:604
Caregiver time use: an outcome measure in clinical trial research on Bayesian approach
Alzheimer’s disease (Clipp and Moore). 1995;58:228-36 Comparison of the Bayesian approach and a simple algorithm for
Clinical pharmacokinetics of physostigmine in patients with assessment of adverse drug events (Lanctét and Naranjo).
Alzheimer’s disease (Asthana et al). 1995;58:299-309 1995;58:692-8
American Society for Clinical Pharmacology and Therapeutics Besipirdine hydrochloride
Future meeting dates and sites of the ASCPT. 1995;58:119, 131 Besipirdine hydrochloride (USAN List No. 374). 1995;58:242
A message from the Finance Committee Chairperson. 1995;58:483
Biphosphonates
A message from the Government Affairs Committee Chairperson.
Studies of the oral bioavailability of alendronate (Gertz et al).
1995;58:118-9
1995;58:288-98
A message from the President—Come to Walt Disney World, March
20-22, 1996. 1995;58:699 Bivalirudin
1996 ASCPT Clinical Pharmacology Curriculum Review Course. Bivalirudin (USAN List No. 374). 1995;58:241
1995;58:700 Blood pressure
1996 ASCPT Workshop on Clinical Pharmacology in Primary Care Biphasic pressor responses to norepinephrine in humans (Sato et al).
Residency Education. 1995;58:700 1995;58:583-7
Nominations for awards. 1995;58:360-1 Books received
Amlexanox Books received. 1995;58:602
Amlexanox (USAN List No. 376). 1995;58:484
Bosentan
Analgesics Bosentan (USAN List No. 375). 1995;58:362
A comparison of crossover versus parallel-group design in the evalua- Brain
tion of analgesic efficacy after molar extraction (Margarone et al). Central nervous system effects of subdissociative doses of (S)-ketamine
1995;58:453-8 are related to plasma and brain concentrations measured with positron
Anastrozole emission tomography in healthy volunteers (Hartvig et al).
Anastrozole (USAN List No. 376). 1995;58:485 1995;58:165-73
CLINICAL PHARMACOLOGY & THERAPEUTICS DECEMBER 1995 711
712 Subject index CLINICAL PHARMACOLOGY & THERAPEUTICS
DECEMBER 1995
Breast feeding Clinical trials
Active transport of cimetidine into human milk (Oo et al). 1995;58:548- Caregiver time use: an outcome measure in clinical trial research on
55 Alzheimer’s disease (Clipp and Moore). 1995;58:228-36
Success rates for new drugs entering clinical testing in the United States
Buccal administration; see Administration, buccal
(DiMasi). 1995;58:1-14 (Commentary)
Cc Commentaries
Commentaries. 1995;58:1-14, 123-6, 243-56, 487-91, 605-16
Caffeine Compliance
Sympathomimetic effects of paraxanthine and caffeine in humans Miscompliance by proxy (Jamieson et al). 1995;58:594
(Benowitz et al). 1995;58:684-91
Congestive heart failure; see Heart failure, congestive
Caregiver time use
Conscious sedation
Caregiver time use: an outcome measure in clinical trial research on
Alzheimer’s disease (Clipp and Moore). 1995;58:228-36 Topographic electroencephalogram of propofol-induced conscious
sedation (Kishimoto et al). 1995;58:666-74
Catecholamines
Intravenous morphine and nalbuphine increase histamine and cate- Contraceptives, oral
cholamine release without accompanying hemodynamic changes Effects of felbamate on the pharmacokinetics of a low-dose combina-
tion oral contraceptive (Saano et al). 1995;58:523-31
(Doenicke et al). 1995;58:81-9
Ceftazidime Correction
Ceftazidime pharmacokinetics in preterm infants: effects of renal func- Population pharmacokinetics of vancomycin in neonates (Seay et al)
tion and gestational age (van den Anker et al). 1995;58:650-9 (1994;56:169-75). 1995;58:142
Central nervous system Correspondence; see Letters
Central nervous system effects of subdissociative doses of (S)-ketamine Creatinine
are related to plasma and brain concentrations measured with positron Association of serum creatinine and age with headache caused by
emission tomography in healthy volunteers (Hartvig et al). nitrates (Pahor et al). 1995;58:470-81
1995;58:165-73 Length/serum creatinine ratio does not predict measured creatinine
Child clearance in critically ill children (Fong et al). 1995;58:192-7
Length/serum creatinine ratio does not predict measured creatinine Cyclic guanosine monophosphate; see Guanosine cyclic mono-
clearance in critically ill children (Fong et al). 1995;58:192-7 phosphate
Norfloxacin interferes with cyclosporine disposition in pediatric
Cyclosporine
patients undergoing renal transplantation (McLellan et al).
1995;58:322-7 Differentiation of absorption and first-pass gut and hepatic metabolism
Pharmacokinetics and pharmacodynamics of 21-day continuous oral in humans: studies with cyclosporine (Wu et al). 1995;58:492-7
etoposide in pediatric patients with solid tumors (Sonnichsen et al). The effects of ketoconazole on the intestinal metabolism and bioavail-
1995;58:99-107 ability of cyclosporine (Gomez et al). 1995;58:15-9
Pharmacokinetics of intravenous ondansetron in healthy children Norfloxacin interferes with cyclosporine disposition in pediatric
undergoing ear, nose, and throat surgery (Spahr-Schopfer et al). patients undergoing renal transplantation (McLellan et al).
1995;58:316-21 1995;58:322-7
China Cytochrome P450
Genetic analysis of the S-mephenytoin polymorphism in a Chinese pop- Comparative effects of omeprazole on xenobiotic metabolizing
ulation (de Morais et al). 1995;58:404-11 enzymes in the rat and human (Kashfi et al). 1995;58:625-30
Propranolol disposition in Chinese subjects of different CYP2D6 geno- Comparison of chloroguartide and mephenytoin for the in vivo assess-
types (Lai et al). 1995;58:264-8 ment of genetically determined CYP2C19 activity in humans
(Partovian et al). 1995;58:257-63
Chloroguanide Comparison of the prevalence of the poor metabolizer phenotype for
Comparison of chloroguanide and mephenytoin for the in vivo assess-
CYP2D6 between 203 Hmong subjects and 280 white subjects resid-
ment of genetically determined CYP2C19 activity in humans ing in Minnesota (Straka et al). 1995;58:29-34
(Partovian et al). 1995;58:257-63
Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6
Chlorpheniramine in humans (Fromm et al). 1995;58:374-82
Chlorpheniramine plasma concentration and histamine H,-receptor In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+)-flu-
occupancy (Yasuda et al). 1995;58:210-20 vastatin (Transon et al). 1995;58:412-7
Cidofovir Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and
Cidofovir (USAN List No. 373). 1995;58:122 in vivo (Mitra et al). 1995;58:556-66
Propranolol disposition in Chinese subjects of different CYP2D6 geno-
Cigarette smoking; see Smoking
types (Lai et al). 1995;58:264-8
Cimetidine Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1
Active transport of cimetidine into human milk (Oo et al). 1995;58:548- activity (Dreisbach et al). 1995;58:498-505
55
Ciprofloxacin D
Effect of probenecid on the distribution and elimination of
ciprofloxacin in humans (Jaehde et al). 1995;58:532-41 Dacliximab
Cisatracurium Dacliximab (USAN List No. 375). 1995;58:363-4
The in vitro degradation of cisatracurium, the R, cis-R’-isomer of Dapsone
atracurium, in human and rat plasma (Welch et al). 1995;58:132-42 Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and
Cisplatin in vivo (Mitra et al). 1995;58:556-66
Effects of cisplatin on urinary thromboxane B, excretion (Bléchl-Daum Delequamine hydrochloride
et al). 1995;58:418-24 Delequamine hydrochloride (USAN List No. 374). 1995;58:242
CLINICAL PHARMACOLOGY & THERAPEUTICS
Subject index 713
VOLUME 58, NUMBER 6
Desirudin Itraconazole and hydroxyitraconazole serum concentrations are reduced
Desirudin (USAN List No. 374). 1995;58:241 more than tenfold by phenytoin (Ducharme et al). 1995;58:617-24
Diabetes Norfloxacin interferes with cyclosporine disposition in pediatric
Tolrestat pharmacokinetic and pharmacodynamic effects on red blood patients undergoing renal transplantation (McLellan et al).
cell sorbitol levels in normal volunteers and in patients with insulin- 1995;58:322-7
dependent diabetes (van Griensven et al). 1995;58:631-40 Sympathomimetic effects of paraxanthine and caffeine in humans
Diazepam (Benowitz et al). 1995;58:684-91
Comparison of the interaction potential of a new proton pump inhibitor, Drug tolerance
E3810, versus omeprazole with diazepam in extensive and poor Pharmacokinetics and pharmacodynamics of the monoamine oxidase B
metabolizers of S-mephenytoin 4 hydroxylation (Ishizaki et al). inhibitor mofegiline assessed during a phase I dose tolerance trial
1995;58:155-64 (Stoltz et al). 1995;58:342-53
Interethnic difference in omeprazole’s inhibition of diazepam metabo-
lism (Caraco et al). 1995;58:62-72
Simultaneous modeling of the pharmacokinetics and pharmacodynam-
ics of midazolam and diazepam (Mould et al). 1995;58:35-43 E3810
Diet Comparison of the interaction potential of a new proton pump inhibitor,
Dietary sodium intake modulates systemic but not forearm norepineph- E3810, versus omeprazole with diazepam in extensive and poor
rine release (Stein et al). 1995;58:425-33 metabolizers of S-mephenytoin 4 hydroxylation (Ishizaki et al).
Effects of dietary fat on drug absorption (Zhi et al). 1995;58:487-91 1995;58:155-64
(Commentary) Comparison of the kinetic disposition and metabolism of E3810, a new
Dihydrocodeine proton pump inhibitor, and omeprazole in relation to S-mephenytoin
Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 4 -hydroxylation status (Yasuda et al). 1995;58:143-54
in humans (Fromm et al). 1995;58:374-82 Ecadotril
Dipyrone Ecadotril (USAN List No. 376). 1995;58:485
Dipyrone metabolism in liver disease (Zylber-Katz et al). 1995;58:198- Electrocardiography
209
Loratadine administered concomitantly with erythromycin: pharmaco-
Drug absorption kinetic and electrocardiographic evaluations (Brannan et al).
Differentiation of absorption and first-pass gut and hepatic metabolism 1995;58:269-78
in humans: studies with cyclosporine (Wu et al). 1995;58:492-7
Electroencephalography
Effects of dietary fat on drug absorption (Zhi et al). 1995;58:487-91
Pharmacodynamic modeling of the electroencephalographic effects of
(Commentary)
flumazenil in healthy volunteers sedated with midazolam (Fiset et al).
Drug availability 1995;58:567-82
Availability of anticancer drugs in the United States, Europe, and
Topographic electroencephalogram of propofol-induced conscious
Japan from 1960 through 1991 (Brown et al). 1995;58:243-56
sedation (Kishimoto et al). 1995;58:666-74
(Commentary)
Embutramide
Drug development
Embutramide (USAN List No. 376). 1995;58:486
Clinical pharmacology and drug safety: lessons from hirudin (Conrad).
1995;58:123-6 (Commentary) Enantiomers
Drug safety discontinuations in the United Kingdom, the United States, Verapamil stereoisomerism: enantiomeric ratios in plasma dependent
and Spain from 1974 through 1993: a regulatory perspective (Bakke on peak concentrations, oral input rate, or both (Karim and Piergies).
et al). 1995;58:108-17 1995;58:174-84
Success rates for new drugs entering clinical testing in the United States
Endothelins
(DiMasi). 1995;58:1-14 (Commentary)
Local angiotensin-converting enzyme inhibition blunts endothelin-
Drug interactions 1-induced increase in forearm vascular resistance (Abernethy et al).
Azithromycin and terfenadine: lack of drug interaction (Harris et al). 1995;58:328-34
1995;58:310-5
Comparison of the interaction potential of a new proton pump inhibitor, Enoxaparin sodium
E3810, versus omeprazole with diazepam in extensive and poor Enoxaparin sodium (USAN List No. 376). 1995;58:485
metabolizers of S-mephenytoin 4 hydroxylation (Ishizaki et al). Entacapone
1995;58: 155-64 The effect of entacapone on the disposition and hemodynamic effects of
The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine (Illi et al). 1995;58:221-7
intravenous isoproterenol and epinephrine (Illi et al). 1995;58:221-7
Enzymes
Effect of probenecid on the distribution and elimination of
Comparative effects of omeprazole on xenobiotic metabolizing
ciprofloxacin in humans (Jaehde et al). 1995;58:532-41
enzymes in the rat and human (Kashfi et al). 1995;58:625-30
Effects of felbamate on the pharmacokinetics of a low-dose combina-
tion oral contraceptive (Saano et al). 1995;58:523-31 Epinephrine
Effects of felbamate on the pharmacokinetics of phenobarbital The effect of entacapone on the disposition and hemodynamic effects of
(Reidenberg et al). 1995;58:279-87 intravenous isoproterenol and epinephrine (Illi et al). 1995;58:221-7
Effects of felbamate on the pharmacokinetics of the monohydroxy and
Eprinomectin
dihydroxy metabolites of oxcarbazepine (Hulsman et al).
Eprinomectin (USAN List No. 376). 1995;58:486
1995;58:383-9
The effects of ketoconazole on the intestinal metabolism and bioavail- Erythrocytes
ability of cyclosporine (Gomez et al). 1995;58:15-9 Tolrestat pharmacokinetic and pharmacodynamic effects on red blood
Interethnic difference in omeprazole’s inhibition of diazepam metabo- cell sorbitol levels in normal volunteers and in patients with insulin-
lism (Caraco et al). 1995;58:62-72 dependent diabetes (van Griensven et al). 1995;58:631-40
714 Sulyect index CLINICAL PHARMACOLOGY & THERAPEUTICS
DECEMBER 1995
Erythromycin Plasma concentrations of triazolam are increased by concomitant inges-
Loratadine administered concomitantly with erythromycin: pharmaco- tion of grapefruit juice (Hukkinen et al). 1995;58:127-31
kinetic and electrocardiographic evaluations (Brannan et al). Fosinopril
1995;58:269-78
Fosinopril: pharmacokinetics and pharmacodynamics in congestive
Erythromycin salnacedin heart failure (Kostis et al). 1995;58:660-5
Erythromycin salnacedin (USAN List No. 375). 1995;58:362
Ethnic factors G
Comparison of the prevalence of the poor metabolizer phenotype for
CYP2D6 between 203 Hmong subjects and 280 white subjects resid- Galdansetron hydrochloride
ing in Minnesota (Straka et al). 1995;58:29-34 Galdansetron hydrochloride (USAN List No. 377). 1995;58:604
Interethnic difference in omeprazole’s inhibition of diazepam metabo- Genetics
lism (Caraco et al). 1995;58:62-72 Genetic analysis of the S-mephenytoin polymorphism in a Chinese pop-
Etoposide ulation (de Morais et al). 1995;58:404-11
Pharmacokinetics and pharmacodynamics of 21-day continuous oral S-Mephenytoin hydroxylation phenotypes in a Jordanian population
etoposide in pediatric patients with solid tumors (Sonnichsen et al). (Hadidi et al). 1995;58:542-7
1995;58:99-107
Gestational age
Europe Ceftazidime pharmacokinetics in preterm infants: effects of renal func-
Availability of anticancer drugs in the United States, Europe, and tion and gestational age (van den Anker et al). 1995;58:650-9
Japan from 1960 through 1991 (Brown et al). 1995;58:243-56
Glomerular filtration rate
(Commentary)
Length/serum creatinine ratio does not predict measured creatinine
Exercise clearance in critically ill children (Fong et al). 1995;58:192-7
Hemoglobin-based oxygen carrier preserves submaximal exercise
capacity in humans (Hughes et al). 1995;58:434-43 Glucocorticoids
Glucocorticoid-induced sympathoinhibition ir humans (Golczynska et
EXP3174
al). 1995;58:90-8
Pharmacokinetics of losartan, an angiotensin II receptor antagonist and
its active metabolite EXP3174 in humans (Lo et al). 1995;58:641-9 Glucose
[{Lys(B28), Pro(B29)|-human insulin: effect of injection time on post-
F prandial glycemia (Howey et al). 1995;58:459-69
Glycemia
Fat [Lys(B28), Pro(B29)|—human insulin: effect of injection time on post-
Effects of dietary fat on drug absorption (Zhi et al). 1995;58:487-91 prandial glycemia (Howey et al). 1995;58:459-69
(Commentary)
Grapefruit juice
Felbamate The fate of naringin in humans: A key to grapefruit juice—drug interac-
Effects of felbamate on the pharmacokinetics of a low-dose combina- tions? (Fuhr and Kummert). 1995;58:365-73
tion oral contraceptive (Saano et al). 1995;58:523-31
Interaction between grapefruit juice and midazolam in humans
Effects of felbamate on the pharmacokinetics of phenobarbital
(Kupferschmidt et al). 1995;58:20-8
(Reidenberg et al). 1995;58:279-87
Plasma concentrations of triazolam are increased by concomitant inges-
Effects of felbamate on the pharmacokinetics of the monohydroxy and
tion of grapefruit juice (Hukkinen et al). 1995;58:127-31
dihydroxy metabolites of oxcarbazepine (Hulsman et al).
1995;58:383-9 Guanosine cyclic monophosphate
Flumazenil Neuropeptide Y in human hand veins: pharmacologic characterization
and interaction with cyclic guanosine monophosphate—dependent
Pharmacodynamic modeling of the electroencephalographic effects of
flumazenil in healthy volunteers sedated with midazolam (Fiset et al). venodilators in vivo (Peduzzi et al). 1995;58:675-83
1995;58:567-82 Guest reviewers
Fluorouracil Guest reviewers. 1995;58:482
Population characteristics of hepatic dihydropyrimidine dehydrogenase
activity, a key metabolic enzyme in 5-fluorouracil chemotherapy (Lu H
et al). 1995;58:512-22
Hand
Fluvastatin
Neuropeptide Y in human hand veins: pharmacologic characterization
In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+)-flu-
vastatin (Transon et al). 1995;58:412-7 and interaction with cyclic guanosine monophosphate-dependent
venodilators in vivo (Peduzzi et al). 1995;58:675-83
Fluvoxamine
Effect of cigarette smoking on fluvoxamine pharmacokinetics in Headache
humans (Spigset et al). 1995;58:399-403 Association of serum creatinine and age with headache caused by
nitrates (Pahor et al). 1995;58:470-81
Fluvoxamine maleate
Fluvoxamine maleate (USAN List No. 376). 1995;58:484 Heart failure, congestive
Fosinopril: pharmacokinetics and pharmacodynamics in congestive
Food and Drug Administration
heart failure (Kostis et al). 1995;58:660-5
Success rates for new drugs entering clinical testing in the United States
(DiMasi). 1995;58:1-14 (Commentary) Heart rate
Food-drug interactions Biphasic pressor responses to norepinephrine in humans (Sato et al).
1995;58:583-7
The fate of naringin in humans: A key to grapefruit juice—drug interac-
tions? (Fuhr and Kummert). 1995;58:365-73 Hemodynamics
Interaction between grapefruit juice and midazolam in humans The effect of entacapone on the disposition and hemodynamic effects of
(Kupferschmidt et al). 1995;58:20-8 intravenous isoproterenol and epinephrine (Illi et al). 1995;58:221-7